TP53 and glioma: Despite the lack of major changes in SM and sulfatide species after TMZ treatment, other studies demonstrated an increase in short-chain fatty acid sphingolipids in glioma cells transfected with p53 and treated with a chemotherapeutic agent (SN-38) [69].